Drugs / KA2237
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02679196 | Jul 2016 → Dec 2018 | B-cell non-Hodgkin lymphoma | Karus Therapeutics Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KA2237 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02679196 ↗ |
| Action | Inhibit | “KA2237 inhibited p110β- and p110δ-dependent AKT activation” PMID 34365878 ↗ Aug 2021 |
| Route | Oral | “KA2237 is an oral, potent, dual p110β/p110δ inhibitor.” PMID 34365878 ↗ Aug 2021 |